StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.0
  1. Startseite
  2. /Verbindung

Oclacitinib Maleate

HCID 44631937
Neue NotizNeue ReaktionAnfrage stellen
Druckvorschau
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1208319-27-0
Standard-SMILES
CNS(=O)(=O)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1.O=C(O)/C=C\C(=O)O
InChIKey
VQIGDTLRBSNOBV-VQIYXBGXNA-N
Summenformel
C19H27N5O6S
Durchschnittliche Molmasse
453,5 g/mol
Monoisotopische Masse
453,16820477

Überblick

See also: Oclacitinib (has active moiety).

Namen und Bezeichner

Bevorzugter Name
Oclacitinib Maleate
IUPAC
(Z)-but-2-enedioic acid;N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide
Englischer Name
Oclacitinib Maleate(PF-03394197)
Summenformel
C19H27N5O6S
Molmasse
453.51

Namen und Synonyme

OCLACITINIB MALEATEUNII-VON733L42AVON733L42APF-03394197-11PF 03394197-11OCLACITINIB MALEATE (EMA EPAR: VETERINARY)N-Methyl(trans-4-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclohexyl) methanesulfonamide (2Z)-2-butenedioateN-Methyl[trans-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclohexyl] methanesulfonamide (2Z)-2-butenedioateRefChem:580731208319-27-01640292-55-2Oclacitinib (maleate)
Weitere Namen anzeigen
N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide MaleateOclacitinib Meleateolatinib maleateOclacitinib Maleate (1:n)Oclacitinib Maleate [VET]Oclacitinib maleate (PF-03394197 maleate)Oclacitinib maleate Good Supplier In China
Oclacitinib maleate [USAN]Apoquel(Z)-but-2-enedioic acid;N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamideN-methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide maleate(1:x)MFCD30533388Cis-Oclacitinib MaleateOclacitinib?maleateOclacitinib Maleate(PF-03394197)

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
174 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
10
Frei drehbare Bindungen
7
Schwere Atome
31
Formalladung
0
Komplexität
606

Experimentelle und physikochemische Eigenschaften

Animal Drugs · 2 Einträge

EMA approved medicines: Veterinary medicine

EMA approved medicines: Veterinary medicine

Physikochemische Eigenschaften

Schmelzpunkt
135 · 135 - 137°C
storage temp.
-20 °C, · -20°C, Inert atmosphere
Löslichkeit
DMSO (Slightly), Methanol (Slightly, Sonicated)
Aggregatzustand
Solid
Farbe
White to Off-White
InChIKey
VQIGDTLRBSNOBV-VQIYXBGXNA-N
SMILES
C(/C(=O)O)=C/C(=O)O.N([C@@H]1CC[C@@H](CS(=O)(=O)NC)CC1)(C1N=CN=C2NC=CC=12)C |&1:9,12,r|

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 6 Einträge

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P260, P264, P264+P265, P270, P273, P280, P301+P317, P305+P354+P338, P317, P319, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

Gefahrenhinweise

Regulatory InformationOclacitinib maleate: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and Categories · 2 Einträge

Acute Tox. 4 (100%)

Acute Tox. 4 (100%)

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302

Chemie und Industrie

Anwendungen · 2 Einträge

BeschreibungAPOQUEL (oclacitinib maleate) was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. It was recently approved for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. In recent years, there has been a significant evolution in understanding regarding the pathophysiology of allergic and atopic diseases. The molecular mechanisms involved in stimulating the itch response have been elaborated (Marsella et al., 2012), and it is now understood that cytokines play a key role in initiating the neuronal itch stimulation which triggers pruritic behavior (scratching, rubbing, chewing, etc.) in dogs. This leads to the establishment of a vicious cycle of itch that exacerbates skin lesions and amplifies defects in the skin barrier function in clinically affected dogs. This progress provided the opportunity to develop new treatments (Marsella et al., 2012). Specifically, Janus kinases play a central role in cytokine signaling and are involved in signal transduction of many pro-inflammatory, pro-allergic, and pruritogenic cytokines including IL-2, IL-4, IL-6, IL-13, and IL-31 that are implicated in allergic conditions (Ong & Leung, 2006; Carmi-Levy et al., 2011).

VerwendenOclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. It is considered to be highly effective in dogs, and has been established as safe for at least short-term use. Its efficacy equals that of prednisolone at first, though oclacitinib has been found to be more effective in the short term in terms of itchiness and dermatitis, long term safety is unknown. It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine. While safe in the short term, oclacitinib's long-term safety is unknown. While some say it is best only for acute flares of itchiness, others claim that it is also useful in chronic atopic dermatitis.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen

Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Weitere Aktionen
Neue NotizNeue ReaktionAnfrage stellen

Datenbank-Bezeichner

CAS
1208319-27-0、1640292-55-2
PubChem CID
44631937
ChEMBL
CHEMBL2105739
UNII
VON733L42A
EC Number
962-495-8、968-552-3